Locoid vs betnovate lotion in the treatment of seborrhoeic and atopic dermatitis of the scalp.

Abstract

In a randomised, double-blind clinical trial, the relative efficacy of Locoid scalp lotion and Betnovate scalp application was assessed in the treatment of 30 patients, 15 in each treatment group, suffering from seborrhoeic or atopic dermatitis of the scalp. Both therapies produced a statistically significant improvement and clearance of the lesions by the end of the four weeks of treatment. Slight differences were observed in favour of Betnovate with respect to global efficacy but this difference was not statistically significant. Side-effects were not spontaneously complained of by any of the 30 patients but six admitted experiencing a stinging or burning sensation (four with Locoid and two with Betnovate) when asked specifically as to the occurrence of these side-effects.

• Authors: B C Turnbull
• Journal: The New Zealand medical journal (N Z Med J) Vol. 95 Issue 718 Pg. 738-40 (Oct 27 1982) ISSN: 0028-8446 [Print] New Zealand
• PMID: 6216427 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• hydrocortisone-17-butyrate
• Betamethasone
• Betamethasone Valerate
• Hydrocortisone

Topics

• Adolescent
• Adult
• Aged
• Betamethasone (analogs & derivatives)
• Betamethasone Valerate (therapeutic use)
• Clinical Trials as Topic
• Dermatitis, Atopic (drug therapy)
• Dermatitis, Seborrheic (drug therapy)
• Double-Blind Method
• Drug Evaluation
• Female
• Humans
• Hydrocortisone (analogs & derivatives, therapeutic use)
• Male
• Middle Aged
• Random Allocation